esmartVeröffentlicht am: 1. Okt. 2016
Biomarker analyses indicate which advanced breast cancer patients are most likely to benefit from CDK4/6 inhibitors
Recent analytical data were presented at this year’s European Society for Medical Oncology Congress, providing an insight into which ABC patients benefit the most from CDK 4/6 inhibitors. The results showed that ER+ patients were more responsive to the treatment, explained Dr Richard Finn, Associate Professor of Haematology and Oncology at the Geffen School of Medicine, UCLA and the Jonsson Comprehensive Cancer Center, US.